tocilizumab
tocilizumab: 33 clinical trials tracked.
tocilizumab evidence translation
What we can confirm
33 tracked trials
What it means
What to watch
Prepared research question
What is verified about tocilizumab, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence8 indications · 2 study sponsors
Clinical Trial Registry Records (33)showing 10 most recent
A Phase 3, Randomized, Open-label, Multicenter Study to Compare the Efficacy and Safety of BMS-986353, CD19-targeted NEX-T CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis (Breakfree-SSc)
Primary endpoint: The absolute change from baseline in Forced Vital Capacity (FVC) in mL
A Phase 1 Open-label Study to Evaluate the Safety and Efficacy of MK-6255 Monotherapy in Advanced Solid Tumors
Primary endpoint: Number of Participants Who Experience a Dose-limiting Toxicity (DLT) as Assessed Using National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), Version 6.0
A Phase 2, Open-label, Multicenter Study to Determine the Safety, Tolerability, and Efficacy of MK-1045 in Participants With Hematologic Malignancies
Primary endpoint: Cohort A Part 1: Number of Participants Who Experience Dose-Limiting Toxicity (DLT)
A Multicenter, Phase 1, Safety and Tolerability Study of CC-97540 (BMS- 986353) in Anti-Aquaporin 4 Antibody Positive Neuromyelitis Optica Patients
Primary endpoint: To evaluate the safety and tolerability of CC-97540 (BMS-986353) in participants with anti-AQP4 antibody positive NMO as determined by the proportion of patients experiencing DLTs
Application of the Personalized N-of-1 Trial Design in Patients With Rheumatoid Arthritis
Primary endpoint: Change in Disease Activity Score (DAS) 28
A Phase II, Nonrandomized, Single-Arm Study of Elranatamab Outpatient Administration in Patients With Relapsed/Refractory Multiple Myeloma (CORE-MM)
Primary endpoint: Incidence of Cytokine Release Syndrome (CRS) in Cycle 1
A Phase 4, Single-Arm, Multicenter Study of Prophylactic Tocilizumab in Participants With Relapsed/Refractory Multiple Myeloma Treated With Linvoseltamab in the Outpatient Setting
Primary endpoint: Occurrence of any grade CRS per American Society for Transplantation and Cellular Therapy (ASTCT) grading
Treatment Strategy for Patients With Rheumatoid Arthritis Associated Interstitial Lung Disease
Primary endpoint: Change in FVC from baseline to week 52
79635322MMY2002: Phase 2 Randomized, Double-blind, Placebo-controlled Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma
Primary endpoint: Percentage of Participants Alive and Free of Treatment-Emergent American Society for Transplantation and Cellular Therapy (ASTCT) Grade Greater Than or Equal to (>=) 2 Cytokine Release Syndrome (CRS)
A Phase 2/3, Randomized, Open-Label, Comparison Study of MK-1045 Versus Blinatumomab in Participants With Relapsed or Refractory CD19+ B-Cell Acute Lymphoblastic Leukemia (B-ALL)
Primary endpoint: Percentage of Participants with Complete Remission (CR) in Study Part 1 and Part 2